Development of Graphene Oxide-Based Anticancer Drug Combination Functionalized with Folic Acid as Nanocarrier for Targeted Delivery of Methotrexate
View/ Open
Access
info:eu-repo/semantics/openAccessDate
2024Author
Yanıkoğlu, ReyhanKarakaş, Canan Yağmur
Çiftçi, Fatih
İnsel, Mert Akın
Karavelioğlu, Zeynep
Varol, Rahmetullah
Yılmaz, Abdurrahim
Çakır, Rabia
Uvet, Hüseyin
Üstündağ, Cem Bülent
Metadata
Show full item recordCitation
YANIKOĞLU, Reyhan, Canan Yağmur KARAKAŞ, Fatih ÇİFTÇİ, Mert Akın İNSEL, Zeynep KARAVELİOĞLU, Rahmetullah VAROL, Abdurrahim YILMAZ, Rabia ÇAKIR, Hüseyin UVET & Cem Bülent ÜSTÜNDAĞ. "Development of Graphene Oxide-Based Anticancer Drug Combination Functionalized with Folic Acid as Nanocarrier for Targeted Delivery of Methotrexate". Pharmaceutics, 16.837 (2024): 1-16.Abstract
Graphene has become a prominent material in cancer research in recent years. Graphene and
its derivatives also attract attention as carriers in drug delivery systems. In this study, we designed
a graphene oxide (GO)-based methotrexate (MTX)-loaded and folic acid (FA)-linked drug delivery
system. MTX and FA were bound to GO synthesized from graphite. MTX/FA/GO drug delivery
system and system components were characterized using Fourier transform infrared spectroscopy
(FTIR), differential calorimetric analysis (DSC), scanning electron microscopy (SEM), transmission
electron microscopy (TEM), zeta potential analysis, and dimension measurement (DLS) studies. SEM
and TEM images confirmed the nanosheet structure of GO synthesized from graphite, and it was
shown that MTX/FA binding to GO transformed the two-dimensional GO into a three-dimensional
structure. FTIR and DSC graphs confirmed that oxygen atoms were bound to GO with the formation
of carboxylic, hydroxyl, epoxide, and carbonyl groups as a result of the oxidation of graphite, and
GO was successfully synthesized. Additionally, these analyses showed that MTX and FA bind
physicochemically to the structure of GO. The in vitro Franz diffusion test was performed as a release
kinetic test. The release kinetics mathematical model and correlation coefficient (R2) of MTX-loaded
GO/FA nanomaterials were found to be the Higuchi model and 0.9785, respectively. Stiffness analyses
showed that adding FA to this release system facilitated the entry of the drug into the cell by directing
the system to target cells. As a result of the stiffness analyses, the stiffness values of the control
cell group, free MTX, and MTX/FA/GO applied cells were measured as 2.34 kPa, 1.87 kPa, and
1.56 kPa, respectively. According to these results, it was seen that MTX/FA/GO weakened the cancer
cells. Combined use of the MTX/FA/GO drug delivery system had a higher cytotoxic effect than
free MTX on the MDA-MB-231 breast cancer cell line. The results showed that the synthesized
MTX/FA/GO material has promising potential in cancer cell-specific targeted therapy for MTX as a
drug delivery system.